Page 5 - Bharat Biotech

No impact on efficacy, safety of Covaxin: Bharat Biotech on WHO suspension

The vaccine manufacturer has said that the company is slowing down the production of Covaxin for facility optimization.

WHO suspends UN supply of Bharat Biotech's Covaxin vaccine for Covid-19

This is to allow the manufacturer to upgrade facilities and address deficiencies found in an inspection

Bharat Biotech slows down COVAXIN production for facility optimisation

Bharat Biotech on Friday announced the temporary slowing down of production of COVAXIN across its manufacturing facilities

Bharat Biotech slows down Covaxin production as it sees decrease in demand

'For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities,' the Hyderabad-based company said

Science more challenging than entrepreneurship, says Krishna Ella

Bharat Biotech may have gained immense popularity with its COVID-19 vaccine Covaxin, but the firm's founder and chairman Krishna Ella says science remains his passion

Bharat Biotech enters into partnership with Biofabri for TB vaccine

This partnership will guarantee the supply of tuberculosis (TB) vaccines in more than 70 countries, especially in Southeast Asia and sub-Saharan Africa

Bharat Biotech sees no impact of Ukraine conflict on vaccine supply chains

Unlike several Western companies, no Indian company has publicly withdrawn from the region.

Global community can tap India's Covid vaccine capacity, say firms

Bharat Biotech MD Krishna Ella said India now has four BSL-4 containment facilities, equal to that of the UK.

Bharat Bio working on TB vaccine, to ink pact with a firm for technology

Without providing details on the name of the firm with which BBIL will be inking MoU, Ella said the TB vaccine is currently undergoing phase 3 clinical trials

Covaxin to be evaluated as Covid vaccine candidate in US: Bharat Biotech

Ocugen Inc is co-developing the Covaxin vaccine candidate for Covid in the US and Canada

Top headlines: L&T Q3 net falls; nod for Bharat Bio's intranasal dose trial

Business Standard brings you the top headlines on Friday

DCGI accords conditional market approval for Covaxin and Covishield

Firms will need to submit data of overseas ongoing clinical trials of their vaccines every 6 months

Neglected infectious diseases may be tomorrow's pandemic: Bharat Bio chief

Bharat Biotech International Limited Chairman Dr Krishna Ella on Monday said today's neglected infectious diseases could be tomorrow's global pandemic

'Hearing that 15-18 age group being given vaccine other than Covaxin'

: Bharat Biotech on Tuesday said it is receiving several reports that children in the age group 15 to 18 are being administered COVID-19 vaccine other than Covaxin. Requesting the health workers to be vigilant and ensure that only Covaxin is administered to that particular age group, Bharat Biotech in a twitter post said its vaccine is the only approved COVID-19 jab to be administered to children in the age group between 15 and 18. "We have received several additional reports of individuals in the 15-18 year age group being administered unapproved COVID-19 vaccines," the company said. Covaxin received approval based on thorough clinical trial evaluation for safety and immunogenicity in the 2-18 years age group. Currently it is the only COVID-19 vaccine in India approved for children, it added.

No full marketing authorisation yet for Covishield and Covaxin vaccines

Review process to continue, experts studying data submitted

Bharat Biotech seeks full marketing approval from DCGI for Covaxin

The company, however, is yet to submit the full follow up data of clinical trila of Covaxin to DCGI, a source said

Covaxin booster neutralises both Omicron and Delta variants: Bharat Biotech

'More than 90% of all individuals boosted with Covaxin showed neutralising antibodies,' says Hyderabad-based Bharat Biotech

Covaxin's makers could earn Rs 7,300 cr by vaccinating children

With a booster dose, the market of 12-18-year-olds represents a revenue pool as much as Rs 11,500 cr

Covaxin booster dose may give long-term immunity: Bharat Biotech

90% of recipients had a detectable neutralising antibody response against the wild-type strain (6 months after the second dose), the Hyderabad-based vaccine maker said

Bharat Biotech gets approval to test nasal Covid-19 shot as booster: Report

The vaccine maker submitted the late-stage trial application to the DCGI in December, adding that an intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns